Scholarlink

Background <p>The integration of immunotherapy with chemotherapy (CT) has emerged as a major focus of clinical research in recent years for patients with advanced or recurrent endometrial cancer (EC). Recent phase 3 randomized controlled trials (RCTs) have reported heterogeneous outcomes, prompting ongoing debate within the oncology community. This study aimed to evaluate the efficacy and safety of this combined approach through a meta-analysis of phase 3 RCTs.</p> Methods <p>A systematic literature search identified phase 3 RCTs comparing first-line immunotherapy plus CT <i>versus</i> CT alone in advanced or recurrent EC. Meta-analyses were performed to pool hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS), odds ratios (ORs) for objective response rate (ORR), and relative risks (RRs) for adverse events (AEs).</p> Results <p>Four phase 3 RCTs (<i>n</i> = 2,334) met eligibility criteria. The combination therapy significantly improved PFS (HR, 0.60; 95% CI, 0.47–0.78), OS (HR, 0.75; 95% CI, 0.65–0.87), and ORR (OR, 1.42; 95% CI, 1.17–1.73) compared to CT alone. While a modest increase in grade 3–5 AEs (RR, 1.11; 95% CI, 1.03–1.20) was observed with combination therapy, there was no significant rise in serious AEs. Subgroup analyses revealed enhanced survival benefits in patients with mismatch repair-deficient (dMMR) tumors, PD-L1-positive tumors, and recurrent disease.</p> Conclusion <p>This meta-analysis demonstrates that combining immunotherapy with CT as first-line treatment for advanced or recurrent EC offers superior efficacy over CT alone while maintaining a comparable toxicity profile. Notably, greater benefits were observed in dMMR, PD-L1-positive, and recurrent disease subgroups.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Combination of immunotherapy and chemotherapy as first-line treatment for advanced or recurrent endometrial cancer: a meta-analysis of phase 3 trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月14日

查看全文
  • Rongxia Li,
  • Xinmiao Zhang,
  • Jinhai Shen

摘要

Background

The integration of immunotherapy with chemotherapy (CT) has emerged as a major focus of clinical research in recent years for patients with advanced or recurrent endometrial cancer (EC). Recent phase 3 randomized controlled trials (RCTs) have reported heterogeneous outcomes, prompting ongoing debate within the oncology community. This study aimed to evaluate the efficacy and safety of this combined approach through a meta-analysis of phase 3 RCTs.

Methods

A systematic literature search identified phase 3 RCTs comparing first-line immunotherapy plus CT versus CT alone in advanced or recurrent EC. Meta-analyses were performed to pool hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS), odds ratios (ORs) for objective response rate (ORR), and relative risks (RRs) for adverse events (AEs).

Results

Four phase 3 RCTs (n = 2,334) met eligibility criteria. The combination therapy significantly improved PFS (HR, 0.60; 95% CI, 0.47–0.78), OS (HR, 0.75; 95% CI, 0.65–0.87), and ORR (OR, 1.42; 95% CI, 1.17–1.73) compared to CT alone. While a modest increase in grade 3–5 AEs (RR, 1.11; 95% CI, 1.03–1.20) was observed with combination therapy, there was no significant rise in serious AEs. Subgroup analyses revealed enhanced survival benefits in patients with mismatch repair-deficient (dMMR) tumors, PD-L1-positive tumors, and recurrent disease.

Conclusion

This meta-analysis demonstrates that combining immunotherapy with CT as first-line treatment for advanced or recurrent EC offers superior efficacy over CT alone while maintaining a comparable toxicity profile. Notably, greater benefits were observed in dMMR, PD-L1-positive, and recurrent disease subgroups.